Advanced Biotherapy Concepts Inc. Announces Appointment of Dr. Paul J. Marangos to its Board of Directors.

Business Editors

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--April 24, 2000

Advanced Biotherapy Concepts Inc. (OTCBB:ADVB) today announced that Paul J. Marangos, Ph.D., founder, past chief executive officer and chairman of the board of directors of Cypros Pharmaceutical Corp. (now merged with Ribogene Inc. to form Questcor Pharmaceuticals)(AMEX:QSC), has been appointed to the company's board of directors.

Cypros was a publicly held company previously listed on the NASDAQ and subsequently on the AMEX prior to its merger with Ribogene.

Edmond Buccellato, CEO of Advanced Biotherapy Concepts, said: "Dr. Marangos' extensive experience in both drug and business development (12 years at the National Institute of Health and 13 years as a senior executive in the biotechnology industry), and his knowledge and experience in capital formation, will be critical to the company as it proceeds to commercialize its drug products."

Buccellato further commented, "The appointment of Dr. Marangos is one of the first steps, among a number of strategic steps to be executed, in repositioning the company from its previous drug discovery mission to that of product commercialization."

ADVB is developing and has patented proprietary treatments for a range of autoimmune diseases, which have now been evaluated in approximately 150 patients that neutralize certain cytokines now confirmed to play a major role in causing these diseases.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product- development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the company's public filings with the Securities and Exchange Commission for information about risks that may affect the company.